Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions
Hepatitis C (HCV) is a widespread health issue, which can lead to hepatic cirrhosis, liver failure, and liver cancer. Nearly 2% of the world's population or > 185 million people are chronically infected with HCV; the management of HCV and the rate of sustained virological response (SVR) were...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ain Shams University
2022-12-01
|
| Series: | Archives of Pharmaceutical Sciences Ain Shams University |
| Subjects: | |
| Online Access: | https://aps.journals.ekb.eg/article_291609.html |
| _version_ | 1797853089388036096 |
|---|---|
| author | Marina Barakat Sara Wahdan Azza Awad Ebtehal El-Demerdash Zaki |
| author_facet | Marina Barakat Sara Wahdan Azza Awad Ebtehal El-Demerdash Zaki |
| author_sort | Marina Barakat |
| collection | DOAJ |
| description | Hepatitis C (HCV) is a widespread health issue, which can lead to hepatic cirrhosis, liver failure, and liver cancer. Nearly 2% of the world's population or > 185 million people are chronically infected with HCV; the management of HCV and the rate of sustained virological response (SVR) were significantly assisted by direct-acting antiviral medications. Since 2014, the FDA has approved using the most potent direct-acting antiviral drug (DAA) combinations. The majority of DAAs can affect cytochrome P450 (CYP) enzymes and are extensively processed by liver enzymes. Additionally, these DAAs are both substrates and drug transporters’ inhibitors, making them a potential target for drug-drug interactions (DDIs). As a result, understanding and managing DDIs with DAAs must be regarded as a crucial aspect of the treatment of HCV. Additionally, patients taking numerous medications or having various co-morbidities must be made aware of the potential consequences of DDIs, such as elevated toxicity or an absence of pharmacological efficacy, in current HCV treatments. |
| first_indexed | 2024-04-09T19:43:55Z |
| format | Article |
| id | doaj.art-f8b9cb63b5714b878e491a36386a0d3f |
| institution | Directory Open Access Journal |
| issn | 2356-8380 2356-8399 |
| language | English |
| last_indexed | 2024-04-09T19:43:55Z |
| publishDate | 2022-12-01 |
| publisher | Ain Shams University |
| record_format | Article |
| series | Archives of Pharmaceutical Sciences Ain Shams University |
| spelling | doaj.art-f8b9cb63b5714b878e491a36386a0d3f2023-04-03T20:40:15ZengAin Shams UniversityArchives of Pharmaceutical Sciences Ain Shams University2356-83802356-83992022-12-016227429110.21608/APS.2023.189971.1106Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug InteractionsMarina Barakat0Sara Wahdan1Azza Awad2https://orcid.org/0000-0001-8224-7055Ebtehal El-Demerdash Zaki3https://orcid.org/0000-0003-2951-4892Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ahram Canadian University, October, EgyptDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, EgyptDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Ahram Canadian University, October, EgyptDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, EgyptHepatitis C (HCV) is a widespread health issue, which can lead to hepatic cirrhosis, liver failure, and liver cancer. Nearly 2% of the world's population or > 185 million people are chronically infected with HCV; the management of HCV and the rate of sustained virological response (SVR) were significantly assisted by direct-acting antiviral medications. Since 2014, the FDA has approved using the most potent direct-acting antiviral drug (DAA) combinations. The majority of DAAs can affect cytochrome P450 (CYP) enzymes and are extensively processed by liver enzymes. Additionally, these DAAs are both substrates and drug transporters’ inhibitors, making them a potential target for drug-drug interactions (DDIs). As a result, understanding and managing DDIs with DAAs must be regarded as a crucial aspect of the treatment of HCV. Additionally, patients taking numerous medications or having various co-morbidities must be made aware of the potential consequences of DDIs, such as elevated toxicity or an absence of pharmacological efficacy, in current HCV treatments.https://aps.journals.ekb.eg/article_291609.htmldaaspharmacokineticspharmacodynamicsp-glycoproteincyp3a4drug interactions |
| spellingShingle | Marina Barakat Sara Wahdan Azza Awad Ebtehal El-Demerdash Zaki Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions Archives of Pharmaceutical Sciences Ain Shams University daas pharmacokinetics pharmacodynamics p-glycoprotein cyp3a4 drug interactions |
| title | Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions |
| title_full | Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions |
| title_fullStr | Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions |
| title_full_unstemmed | Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions |
| title_short | Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions |
| title_sort | direct acting antiviral drugs pharmacokinetics and drug drug interactions |
| topic | daas pharmacokinetics pharmacodynamics p-glycoprotein cyp3a4 drug interactions |
| url | https://aps.journals.ekb.eg/article_291609.html |
| work_keys_str_mv | AT marinabarakat directactingantiviraldrugspharmacokineticsanddrugdruginteractions AT sarawahdan directactingantiviraldrugspharmacokineticsanddrugdruginteractions AT azzaawad directactingantiviraldrugspharmacokineticsanddrugdruginteractions AT ebtehaleldemerdashzaki directactingantiviraldrugspharmacokineticsanddrugdruginteractions |